We’ve partnered with the USA-based Institute for Clinical and Economic Review (ICER) and the Canadian Drug Agency (CDA-AMC) to establish the Health Economics Methods Advisory (HEMA), a new ...
This topic was evaluated as a single technology evaluation by the highly specialised technologies evaluation committee, which is a standing advisory committee of NICE. Committee members are asked to ...
NICE announces proposals to transform its HealthTech programme to drive more technology into the NHS
Consultation launches on the biggest shake-up of NICE's HealthTech programme to date. More innovative healthcare technologies could soon be adopted by the NHS under reforms proposed today by NICE.
Olaparib for treating BRCA mutation-positive HER2-negative advanced breast cancer after chemotherapy
Section 7 of the National Institute for Health and Care Excellence (Constitution and Functions) and the Health and Social Care Information Centre (Functions) Regulations 2013 requires integrated care ...
Olaparib for treating BRCA mutation-positive HER2-negative advanced breast cancer after chemotherapy
There is a commercial access agreement for olaparib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
A resource impact template has not been produced for this appraisal. The resource impact template for selpercatinib for advanced thyroid cancer with RET alterations untreated with a targeted cancer ...
The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee B. Committee members are asked to declare any interests in the technology to be ...
The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by the lead team of committee D, which includes the vice chair. Committee members are asked to ...
Olaparib for treating BRCA mutation-positive HER2-negative advanced breast cancer after chemotherapy
Olaparib (Lynparza, AstraZeneca) is indicated as 'monotherapy for the treatment of adult patients with germline BRCA1/2 mutations, who have HER2 negative locally advanced or metastatic breast cancer.
Ganaxolone (Ztalmy, Orion and Marinus) is indicated for the 'adjunctive treatment of epileptic seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients 2 ...
Olaparib for treating BRCA mutation-positive HER2-negative advanced breast cancer after chemotherapy
This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'Inputs and eligible population' and 'Unit costs' worksheets in the template to reflect ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results